Article
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Arthritis & rheumatology (Hoboken, N.J.) - 1 Jul 2021
Bing Nan, Zhou Huanyu, Chen Xing, Hirose Tomohiro, Kochi Yuta, Tsuchida Yumi, Ishigaki Kazuyoshi, Sumitomo Shuji, Fujio Keishi, Zhang Baohong, Valdez Hernan, Vincent Michael S, Martin David, Clark James D
Abstract excerpt
OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis, and has been previously investigated for psoriasis (PsO). This meta-analysis of genome-wide association studies (GWAS) was performed to identify genetic factors associated with increased risk/faster onset of herpes zoster (HZ) in subjects with RA or PsO receiving tofacitinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.